Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite

Erlotinib in the first-line treatment of non-small-cell lung cancer

By D'Arcangelo Manolo   Cappuzzo Federico  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 5, 2013-05 ,pp. : 523-533

Informa Healthcare

Access to resources Recommend Favorite

A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer

By            

Oncology Reports, Vol. 28, Iss. 3, 2012-01 ,pp. : 763-767

Spandidos Publications

Access to resources Recommend Favorite

Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 14, Iss. 5, 2014-06 ,pp. : 646-650

Bentham Science Publishers

Access to resources Recommend Favorite

Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite